Neumora Therapeutics, a clinical-stage biopharmaceutical company redefining neuroscience drug development, announced the appointment of Kaya Pai Panandiker as chief commercial officer and a member of Neumora’s executive team, reporting to Henry Gosebruch, president and CEO.
“I am excited to welcome Kaya to Neumora. As we progress toward the potential commercialization of navacaprant and further advance our pipeline, her extensive commercial expertise in neuropsychiatry will be invaluable,” said Henry Gosebruch, president and chief executive officer, Neumora.
Ms. Pai Panandiker brings extensive commercial strategy and execution expertise to Neumora, having led the launches of multiple neuropsychiatry products throughout her career. Prior to joining Neumora, Ms. Pai Panandiker served as head of commercial at Cerevel Therapeutics and general manager, neuroscience at Lundbeck US. During her time at Lundbeck, Ms. Pai Panandiker led commercialization efforts for its neuroscience franchise, achieving blockbuster sales.
“It is an incredibly exciting time to join Neumora as we progress pivotal studies in MDD and advance a deep pipeline in schizophrenia, Alzheimer’s, Parkinson’s and other disease areas with significant unmet medical need,” said Kaya Pai Panandiker, chief commercial officer, Neumora. “I am impressed with Neumora’s progress to date and look forward to leading a commercial team with the potential to transform the standard of care for millions of patients living with brain diseases.”
Ms. Pai Panandiker holds a master’s in public policy from University of Chicago and a bachelor’s in American studies from University of Wisconsin-Madison.
Neumora Therapeutics, Inc. is a clinical-stage biopharmaceutical company founded to confront the global brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed.
👉 Neumora Therapeutics Appoints Kaya Pai Panandiker as Chief Commercial Officer | Neumora Therapeutics, Inc. (neumoratx.com)
